Document Detail


Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
MedLine Citation:
PMID:  17728608     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Somatostatin receptor scintigraphy (SRS) is well-established in neuroendocrine tumour (NET) imaging. This study evaluated the impact of attenuation correction (AC) on SRS SPECT data in patients examined by SPECT-CT. METHODS: Planar scintigraphy and SPECT-CT of 17 patients (10 men, seven women; age, 40-74 years; mean, 62 years) suffering from NET were included. For the visual assessment of AC, the intensity and contrast of foci classified as pathological were rated in both the non-attenuation corrected (NAC) and the attenuation corrected (AC) SPECT images using a 5-point score. The change in signal intensity after AC was semiquantified two-fold for each focus in both SPECT(AC) and SPECT(NAC): firstly by using tumour-to-background (TB) ratios (defined as T(max)/B(mean)) for the determination of a TB(AC)/TB(NAC) ratio. Secondly, by a T(max,AC)/T(max,NAC) ratio. Both ratios were correlated to the focus depth. RESULTS: A total of 46 pathological foci were found. Focus contrast and intensity significantly increased in 14/46 foci (30%) after AC (mean, 3.7-4.0) in the visual analysis (P<0.001). While TB ratios increased only in 24/46 foci after AC and no correlation between the T(BAC)/T(BNAC) ratio and focus depth (r=0.027; P=0.856) was found, T(max) was higher after AC in all foci and the T(max,AC)/T(max,NAC) ratio showed the expected correlation to focus depth (r=0.650; P<0.01), indicating the superiority of the Tmax approach for the demonstration of the effects of attenuation correction on focal uptake. CONCLUSION: Attenuation correction of SRS SPECT data by SPECT-CT results in visually more clearly contrasted foci. Moreover, as focus intensity increases, especially in the more centrally localised foci, CT-based AC has a potential to further improve the sensitivity of SRS SPECT.
Authors:
Juri Ruf; Ingo Steffen; Sebastian Mehl; Christian Rosner; Timm Denecke; Ulrich-Frank Pape; Michail Plotkin; Holger Amthauer
Related Documents :
20676638 - Prospective study of p-[123i]iodo-l-phenylalanine and spect for the evaluation of newly...
16954918 - Comparison between contrast-enhanced magnetic resonance imaging and technetium 99m gluc...
6604138 - Detection of severe cornary heart disease with ti-201: comparison of resting single pho...
19052938 - Functional mechanism of lung mosaic ct attenuation: assessment with deep-inspiration br...
22932738 - Assessment of grating-based x-ray phase-contrast ct for differentiation of invasive duc...
19959518 - Hepatobiliary-specific mr contrast agents: role in imaging the liver and biliary tree.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nuclear medicine communications     Volume:  28     ISSN:  0143-3636     ISO Abbreviation:  Nucl Med Commun     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-08-30     Completed Date:  2007-11-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  England    
Other Details:
Languages:  eng     Pagination:  782-8     Citation Subset:  IM    
Affiliation:
Klinik für Strahlenheilkunde, Charité, Centrum 6 für diagnostische und interventionelle Radiologie und Nuklearmedizin, Charité--Universitätsmedizin Berlin, Germany. juri.ruf@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Artifacts*
Female
Humans
Image Enhancement / methods*
Male
Middle Aged
Neuroendocrine Tumors / diagnosis*,  metabolism
Radiation Dosage
Radiopharmaceuticals / diagnostic use,  pharmacokinetics
Receptors, Somatostatin / metabolism*
Reproducibility of Results
Sensitivity and Specificity
Somatostatin / analogs & derivatives*,  diagnostic use,  pharmacokinetics
Subtraction Technique
Tomography, Emission-Computed, Single-Photon / methods*
Tomography, X-Ray Computed / methods*
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 0/Receptors, Somatostatin; 138661-02-6/pentetreotide; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  99mTc(V)-DMSA SPECT for the assessment of disease activity in Graves' ophthalmopathy.
Next Document:  Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET...